Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: anetwork meta-analysis of randomized controlled trials.

Abstract

This study aimed to assess the relative efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis (RA). We performed aBayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of olokizumab administered intravenously to RA patients at 64 mg/kg every 2 or 4weeks (Q2 or Q4W). Five RCTs comprising 2609patients met the inclusion criteria. Both olokizumab Q2 and Q4W treatments achieved asignificant American College of Rheumatology 20% response (ACR20) compared with the placebo (odds ratio [OR] 3.21, 95% credible interval [CrI] 2.53-4.09; OR 3.05, 95% CrI 2.43-3.86). However, olokizumab Q2W was associated with the most favorable surface using the cumulative ranking curve (SUCRA) for the ACR20 response rate. The ranking probability based on the SUCRA indicated that olokizumab Q2W had the highest probability of being considered the best treatment option for achieving the ACR20 response rate, followed by olokizumab Q4W, adalimumab, and placebo. The ACR50 and 70response rates showed asimilar distribution pattern to the ACR20 response rate, except that olokizumab Q4W had ahigher-ranking probability than olokizumab Q2W for ACR50. The SUCRA rating likelihood of adverse events (AEs) and withdrawal due to AEs showed that aplacebo was likely to be the best intervention. Both olokizumab Q2 and Q4W were efficacious and well-tolerated treatments for active RA.